Cargando…
The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting
There is substantive and accumulating evidence that endemic exposure to plastic-associated chemicals (PACs) contribute to the pathophysiology of metabolic conditions, like obesity, diabetes, and heart disease. The consequences of this endemic exposure in inducing a pro-inflammatory state in adipose...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915988/ https://www.ncbi.nlm.nih.gov/pubmed/35034036 http://dx.doi.org/10.1097/MED.0000000000000712 |
_version_ | 1784668184572329984 |
---|---|
author | Lucas, Andrew Herrmann, Susan Lucas, Michaela |
author_facet | Lucas, Andrew Herrmann, Susan Lucas, Michaela |
author_sort | Lucas, Andrew |
collection | PubMed |
description | There is substantive and accumulating evidence that endemic exposure to plastic-associated chemicals (PACs) contribute to the pathophysiology of metabolic conditions, like obesity, diabetes, and heart disease. The consequences of this endemic exposure in inducing a pro-inflammatory state in adipose tissues as a critical link between exposure and disease is reviewed. RECENT FINDINGS: In general, PACs are classified as nonpersistent in vivo because of their rapid metabolism to easily excreted forms. The parental chemicals, however, are typically lipophilic, with the potential to bioaccumulate. Recent data from selected association studies suggest exposure to PACs drive predisease states like obesity and inflammation of the adipose tissues. A range of experimental studies are discussed with a focus on biological mechanisms that are susceptible to the influence of PACs and which may promote metabolic disease, the detection of PACs within susceptible tissues and biological effects that are detectable at doses that correspond to real-life exposures to these chemicals. SUMMARY: If we hypothesize the toxic pressure from chronic exposure to PACs will progress disease processes, then individuals with comprehensively characterized indicators of premetabolic disease could undergo trials of quantifiable interventions to reduce exposure to PACs to test if the trajectory of disease-associated analytes, is altered. |
format | Online Article Text |
id | pubmed-8915988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-89159882022-03-18 The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting Lucas, Andrew Herrmann, Susan Lucas, Michaela Curr Opin Endocrinol Diabetes Obes LIPIDS: Edited by Gerald F. Watts There is substantive and accumulating evidence that endemic exposure to plastic-associated chemicals (PACs) contribute to the pathophysiology of metabolic conditions, like obesity, diabetes, and heart disease. The consequences of this endemic exposure in inducing a pro-inflammatory state in adipose tissues as a critical link between exposure and disease is reviewed. RECENT FINDINGS: In general, PACs are classified as nonpersistent in vivo because of their rapid metabolism to easily excreted forms. The parental chemicals, however, are typically lipophilic, with the potential to bioaccumulate. Recent data from selected association studies suggest exposure to PACs drive predisease states like obesity and inflammation of the adipose tissues. A range of experimental studies are discussed with a focus on biological mechanisms that are susceptible to the influence of PACs and which may promote metabolic disease, the detection of PACs within susceptible tissues and biological effects that are detectable at doses that correspond to real-life exposures to these chemicals. SUMMARY: If we hypothesize the toxic pressure from chronic exposure to PACs will progress disease processes, then individuals with comprehensively characterized indicators of premetabolic disease could undergo trials of quantifiable interventions to reduce exposure to PACs to test if the trajectory of disease-associated analytes, is altered. Lippincott Williams & Wilkins 2022-04 2022-02-14 /pmc/articles/PMC8915988/ /pubmed/35034036 http://dx.doi.org/10.1097/MED.0000000000000712 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | LIPIDS: Edited by Gerald F. Watts Lucas, Andrew Herrmann, Susan Lucas, Michaela The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title | The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title_full | The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title_fullStr | The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title_full_unstemmed | The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title_short | The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
title_sort | role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting |
topic | LIPIDS: Edited by Gerald F. Watts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915988/ https://www.ncbi.nlm.nih.gov/pubmed/35034036 http://dx.doi.org/10.1097/MED.0000000000000712 |
work_keys_str_mv | AT lucasandrew theroleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting AT herrmannsusan theroleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting AT lucasmichaela theroleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting AT lucasandrew roleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting AT herrmannsusan roleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting AT lucasmichaela roleofendocrinedisruptingphthalatesandbisphenolsincardiometabolicdiseasetheevidenceismounting |